The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Performance of a trained large language model to provide clinical trial recommendation in a head and neck cancer population.
 
Tony Hung
Stock and Other Ownership Interests - TeamX Medical Group
Consulting or Advisory Role - Regeneron
Patents, Royalties, Other Intellectual Property - LookUpTrials - Patent pending
 
Gilad Kuperman
No Relationships to Disclose
 
Eric Jeffrey Sherman
Consulting or Advisory Role - AffyImmune Therapeutics; Blueprint Medicines; Eisai; Exelixis; Lilly; UpToDate
Research Funding - Fore Biotherapeutics (Inst); HUTCHMED (Inst); Lilly (Inst); Novartis (Inst); Regeneron (Inst)
 
Alan Loh Ho
Stock and Other Ownership Interests - Rgenta
Honoraria - Chinese American Hematology and Oncology Network; Endocrine Society (Clinical Endocrinology Update); Physicans' Education Resource
Consulting or Advisory Role - AffyImmune Therapeutics; Cellestia Biotech; Coherus Biosciences; Eisai; Eisai; Elevar Therapeutics; Exelixis; ExpertConnect; InxMed; Kura Oncology; Merck; Nested Therapeutics; Prelude Therapeutics; Remix Therapeutics; Rgenta
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; BioAtla; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Elevar Therapeutics; Genentech/Roche; Kura Oncology; Merck; Novartis; OncC4; Poseida; TILT Biotherapeutics; Verastem
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
 
Winston Wong
Research Funding - BioAtla
 
Anuja Kriplani
No Relationships to Disclose
 
Lara Dunn
Consulting or Advisory Role - Merck
Research Funding - CUE Biopharma; Nektar; Regeneron; Replimune; Seagan; Seagan
 
James Vincent Fetten
No Relationships to Disclose
 
Loren S. Michel
Consulting or Advisory Role - KisoJi Biotechnology
Research Funding - Exelixis (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Shrujal S. Baxi
Employment - Flatiron Health; Iterative Health; Verana Health
Stock and Other Ownership Interests - Roche
 
Chunhua Weng
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - MeiraGTx; Nykode Therapeutics
Research Funding - Akeso Biopharma; AstraZeneca (Inst); Atara Biotherapeutics (Inst); Bayer (Inst); Eisai (Inst); Hookipa Pharma (Inst); Lilly (Inst); MedImmune (Inst); MeiraGTx (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Jun J. Mao
Research Funding - Tibet Cheezheng Tibetan Medicine Co., Ltd. (Inst)